Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) FCF Margin (2020 - 2025)

Historic FCF Margin for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to 23.62%.

  • Apellis Pharmaceuticals' FCF Margin rose 63000.0% to 23.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.74%, marking a year-over-year increase of 364800.0%. This contributed to the annual value of 11.3% for FY2024, which is 1388600.0% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its FCF Margin stood at 23.62% for Q3 2025, which was up 63000.0% from 2.46% recorded in Q2 2025.
  • Apellis Pharmaceuticals' FCF Margin's 5-year high stood at 23.62% during Q3 2025, with a 5-year trough of 20695.99% in Q2 2021.
  • Its 5-year average for FCF Margin is 1526.11%, with a median of 155.85% in 2023.
  • Over the last 5 years, Apellis Pharmaceuticals' FCF Margin had its largest YoY gain of 200378900bps in 2022, and its largest YoY loss of -4381600bps in 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' FCF Margin (Quarter) stood at 186.63% in 2021, then tumbled by -235bps to 624.78% in 2022, then soared by 89bps to 66.93% in 2023, then skyrocketed by 114bps to 9.1% in 2024, then surged by 160bps to 23.62% in 2025.
  • Its FCF Margin stands at 23.62% for Q3 2025, versus 2.46% for Q2 2025 and 32.03% for Q1 2025.